

# Invitation

At Pfizer we are passionate about bringing innovative breakthrough medicines to patients.

This is an exciting time for acute leukemia communities as we enter a new era of therapy in which more effective, targeted options are becoming available or patients. In our symposium, we will discuss novel antibody based therapies in acute leukemias, and how treatment outcomes can be improved for relapsed/refractory ALL patients.

Pfizer Satellite Symposium,  
Antibody directed approach  
in acute lymphoid leukemias

On behalf of Pfizer, we would like to invite you to attend the Pfizer satellite symposium taking place on October 19<sup>th</sup> during the 11<sup>th</sup> Baltic Conference of Hematology 2018 at Radisson Blu Sky Hotel in Tallinn, Estonia.

This satellite symposium is restricted to participants eligible to prescribe medicines



## Program:

Chair: Dr. Mariken Ross

17:45–17:50 Welcome and introduction – Dr. Mariken Ross

17:50–18:00 Antibody drug conjugates – Dr. Mariken Ross

18:00–18:25 Improving therapy outcomes in R/R ALL – Prof. David Marks

18:25–18.30 Discussion



**Dr. Mariken Ross,**  
Head of the Hematology Department,  
North Estonian Medical Center

Dr. Mariken Ross got her medical degree in the University of Tartu in 2009. Her further training continued in cooperation with several hematology centres, including Bologna University Hospital and Karolinska University Hospital. She was part of the Blood Cancer Network Ireland team, working in close collaboration with prof O'Dwyer and the clinical trials unit to make new treatment and research options accessible for more patients.

She is currently the Head of Hematology Department in the largest hospital in Estonia – North Estonian Medical Center and is a valued expert in North Estonian Medical Center hematological malignancies interdisciplinary working-group.

Her expertise and interest in the environmental and epidemiological aspects in medicine as well as love for teaching are highly acknowledged and she's been valued lecturer in Estonian Entrepreneurship University of Applied Sciences since 2006. Her ongoing projects on that field include Entrepreneurship Education Program in Estonia and she is also participating in a project named: "Let's dream together – for better education".



**Professor David Marks,**  
Bristol BMT Unit, NCRI ALL group UK,  
Medical Director Impact UK

Professor David Marks received his medical education at the University of Melbourne and his clinical training largely at the Royal Melbourne Hospital. He was awarded his FRACP in 1988 and his PhD in 'Mechanisms of cytotoxic drug action' in 1990. He then moved to London to receive further training in stem cell transplantation with Professor Goldman at the Hammersmith Hospital as MRC/LRF fellow and senior registrar. 3 years stint in Philadelphia as Assistant Professor in Hem/ Onc enabled him to set up a new unrelated donor transplant program and do p53 research in ALL. He returned to the UK in 1996 & was appointed as consultant in the Bristol BMT Unit (which he directs) and Hon Senior Lectureship at the Uni of Bristol. His research & scientific papers focus on clinical aspects of stem cell transplantations (esp the use of alternative donors), ALL & infection. In 1999 he initiated the Clinical trials committee of the British Society of BMT, the 1<sup>st</sup> national transplant trial group and chaired that group for 5 years. In 2004 he was promoted to Reader and in 2007 to Professor at the University and was Lead Clinician of the Bristol BMT Unit from 2003-9 and 2014-16. He received FRCPath in 2006. He is Transplant coordinator and Deputy Chair of NCRI ALL working group and from 2007-2009 was President of BSBMT. He chairs the BSBMT Adjudication committee. He previously was Vice Chair (Europe) of the Advisory Committee of the CIBMTR and Scientific Secretary for EBMT London 2013. He was the CI of the Improvit study, a large multinational study of fungal prophylaxis. In 2017 he co-chaired the Tandem BMT meetings in Orlando.